正大天晴 HER2 双抗首次启动 III 期临床

Insight数据库
04 Jul

近日,正大天晴在ClinicalTrials.gov 官网上登记了一项TQB2930 用于HER2 阳性乳腺癌的 III 期临床试验(NCT07047365)。公开资料显示,这是该药启动的首个III 期。截图来源:ClinicalTrials.gov 官网这是一项随机、开放、平行对照、多中心 III 期临床研究,旨在评估 TQB2930 联合研究者选择的化疗与曲妥珠单抗联合研究者选择的化疗治疗 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10